Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» NewAmsterdam Pharma
NewAmsterdam Pharma
IPOs vs SPACs
IPOs vs SPACs
EP Vantage
IPOs
SPAC
Belite Bio
Cerevel Therapeutics
NewAmsterdam Pharma
Nuvectis Pharma
Oculis
Roivant Sciences
Flag link:
NewAmsterdam's Amgen castoff cuts LDL cholesterol in phase 2, opening new front in race to market
NewAmsterdam's Amgen castoff cuts LDL cholesterol in phase 2, opening new front in race to market
Fierce Biotech
NewAmsterdam Pharma
Amgen
CETP inhibitors
obicetrapib
clinical trials
Flag link:
NewAmsterdam Pharma to Merge With SPAC Frazier Lifesciences
NewAmsterdam Pharma to Merge With SPAC Frazier Lifesciences
Marketwatch
NewAmsterdam Pharma
M&A
SPAC
Frazier Lifesciences
Flag link:
A much-hyped CV drug failed, repeatedly. Now, investors are betting nearly $200M on one last PhIII bid
A much-hyped CV drug failed, repeatedly. Now, investors are betting nearly $200M on one last PhIII bid
Endpoints
Eli Lilly
cardiovascular disease
NewAmsterdam Pharma
CETP inhibitors
Flag link:
A new biotech forms to revive Amgen's old heart drug
A new biotech forms to revive Amgen's old heart drug
BioPharma Dive
Amgen
NewAmsterdam Pharma
obicetrapib
heart disease
Flag link:
